Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Solid Biosciences Inc (SLDB)

Solid Biosciences Inc (SLDB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 121,167
  • Shares Outstanding, K 46,071
  • Annual Sales, $ 0 K
  • Annual Income, $ -117,220 K
  • 60-Month Beta 1.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.47
  • Number of Estimates 2
  • High Estimate -0.41
  • Low Estimate -0.53
  • Prior Year -0.76
  • Growth Rate Est. (year over year) +38.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.29 +12.23%
on 07/29/20
3.14 -18.15%
on 07/20/20
-0.43 (-14.33%)
since 07/02/20
3-Month
2.29 +12.23%
on 07/29/20
3.57 -28.01%
on 06/23/20
+0.24 (+10.30%)
since 05/01/20
52-Week
1.96 +31.12%
on 03/12/20
13.58 -81.08%
on 10/23/19
-3.41 (-57.02%)
since 08/02/19

Most Recent Stories

More News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Solid Biosciences Inc. - SLDB

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Solid Biosciences Inc. ("Solid Biosciences" or the "Company") (NASDAQ: SLDB).  Such investors are advised to contact...

SLDB : 2.58 (-1.90%)
Solid Biosciences Provides Update Regarding the IGNITE DMD Phase I/II Clinical Hold

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, today announced that it received written communication from the...

SLDB : 2.58 (-1.90%)
Sarepta Inks Agreement With Codiak to Develop Gene Therapies

Sarepta (SRPT) and Codiak BioSciences sign agreement to develop potential gene therapies targeting neuromuscular indications using Codiak's engineered exosomes.

RHHBY : 44.0480 (+2.20%)
PFE : 38.34 (-0.36%)
SRPT : 157.20 (+2.40%)
SLDB : 2.58 (-1.90%)
Solid Biosciences Announces Appointment of Ian F. Smith as Chairman of the Board of Directors

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced today the appointment of board member Ian F. Smith as...

SLDB : 2.58 (-1.90%)
Sarepta's Gene Therapy Promising in Muscular Dystrophy Study

Sarepta's (SRPT) gene therapy candidate for treating limb-girdle muscular dystrophy shows continued functional improvement over a year for the lower dose as well as increasing efficacy with higher dose....

RHHBY : 44.0480 (+2.20%)
PFE : 38.34 (-0.36%)
SRPT : 157.20 (+2.40%)
SLDB : 2.58 (-1.90%)
Why Solid Biosciences (SLDB) Stock Might be a Great Pick

Solid Biosciences (SLDB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

SLDB : 2.58 (-1.90%)
Solid Biosciences to Hold Virtual Annual Meeting of Stockholders on June 16, 2020

Solid Biosciences Inc. (Nasdaq: SLDB) today announced that, due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who...

SLDB : 2.58 (-1.90%)
Pfizer Reports Efficacy & Safety Data on DMD Gene Therapy

Pfizer's (PFE) new phase Ib data on its investigational gene therapy, PF-06939926 in ambulatory boys with DMD support advancement to a pivotal phase III study.

PFE : 38.34 (-0.36%)
SRPT : 157.20 (+2.40%)
PTCT : 47.07 (+1.60%)
SLDB : 2.58 (-1.90%)
Solid Biosciences Presents Data from Duchenne Muscular Dystrophy Gene Therapy Program at ASGCT 23rd Annual Meeting

Virtual oral presentation reviews interim clinical biomarker data for SGT-001 and provides data on expression and co-localization of microdystrophin and dystrophin associated proteins in patients in the...

SLDB : 2.58 (-1.90%)
Top Ranked Momentum Stocks to Buy for May 13th

Top Ranked Momentum Stocks to Buy for May 13th

SLDB : 2.58 (-1.90%)
MRSN : 20.33 (+2.26%)
ISEE : 4.28 (+6.73%)
IDCC : 61.70 (+2.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade SLDB with:

Business Summary

Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001,...

See More

Key Turning Points

2nd Resistance Point 2.80
1st Resistance Point 2.71
Last Price 2.58
1st Support Level 2.50
2nd Support Level 2.38

See More

52-Week High 13.58
Fibonacci 61.8% 9.14
Fibonacci 50% 7.77
Fibonacci 38.2% 6.40
Last Price 2.58
52-Week Low 1.96

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar